- Home
- IPSC vs QNCX Comparison
IPSC vs QNCX Comparison
Compare IPSC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- QNCX
- Stock Information
- Founded
- IPSC 2019
- QNCX 2012
- Country
- IPSC United States
- QNCX United States
- Employees
- IPSC N/A
- QNCX N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IPSC Health Care
- QNCX Health Care
- Exchange
- IPSC Nasdaq
- QNCX Nasdaq
- Market Cap
- IPSC 47.4M
- QNCX 47.7M
- IPO Year
- IPSC 2021
- QNCX 2019
- Fundamental
- Price
- IPSC $0.59
- QNCX $1.73
- Analyst Decision
- IPSC Strong Buy
- QNCX Strong Buy
- Analyst Count
- IPSC 5
- QNCX 5
- Target Price
- IPSC $3.33
- QNCX $8.00
- AVG Volume (30 Days)
- IPSC 1.0M
- QNCX 294.4K
- Earning Date
- IPSC 08-07-2025
- QNCX 08-12-2025
- Dividend Yield
- IPSC N/A
- QNCX N/A
- EPS Growth
- IPSC N/A
- QNCX N/A
- EPS
- IPSC N/A
- QNCX N/A
- Revenue
- IPSC $114,898,000.00
- QNCX N/A
- Revenue This Year
- IPSC $1,590.09
- QNCX N/A
- Revenue Next Year
- IPSC N/A
- QNCX N/A
- P/E Ratio
- IPSC N/A
- QNCX N/A
- Revenue Growth
- IPSC 8286.72
- QNCX N/A
- 52 Week Low
- IPSC $0.34
- QNCX $0.51
- 52 Week High
- IPSC $3.29
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- IPSC 55.59
- QNCX 64.55
- Support Level
- IPSC $0.59
- QNCX $1.55
- Resistance Level
- IPSC $0.57
- QNCX $2.05
- Average True Range (ATR)
- IPSC 0.04
- QNCX 0.16
- MACD
- IPSC 0.00
- QNCX 0.01
- Stochastic Oscillator
- IPSC 66.59
- QNCX 49.21
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.